Partnering

The OmniAb platforms are licensed to a wide range of biopharmaceutical companies and academics. OmniAb is offered with flexible terms for all targets, indications, and territories in three principal ways:


Unlimited License

  • Annual access fee
  • Clinical milestones
  • Royalty on sales

Individual Target License

  • Target fee
  • Clinical milestones
  • Royalty on sales

Unlimited Buy-out

  • Buy-out fee
  • Single- or multi-year
  • NO milestones or royalties

To explore specific licensing terms, please facilitate execution of the OmniAb term sheet CDA available in the download section and E-mail omniab@ligand.com.

Partners

Merck
Pfizer
Celgene
Amgen
Genmab
Janssen
FivePrime
Aptevo Therapeutics
SeattleGenetics
Symphogen
Armo Biosciences
Hanall Pharmaceutical
Gloria Pharmaceuticals
Tizona
ABBA
F-star
Gilead
Ono
AbbVie
BlueBirdBio
Charite
Genentech
Roche
Teneo
Teva
xCella
Surface Oncology

OmniAb is partnered with a range of large and small biopharmaceutical companies globally. For more information, including regarding OmniAb platform access, please E-mail omniab@ligand.com.